Overview

A Trial to Assess the Antipsychotic Efficacy of ITI-007

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
Phase:
Phase 3
Details
Lead Sponsor:
Intra-Cellular Therapies, Inc.
Treatments:
Antipsychotic Agents